Fresh from Vertex payday, Entrada's DMD plans are derailed by FDA hold

You could have forgiven Entrada Therapeutics for feeling it was riding high this month after banking a $224 million payment from Vertex for a preclinical myotonic dystrophy candidate. But the company has now been dragged back to Earth thanks to a clinical hold placed by the FDA on its program for another muscle disorder.